VAXXINITY INC-A (VAXX)

US92244V1044 - Common Stock

0.1111  -0.02 (-15.26%)

After market: 0.1107 0 (-0.36%)

News Image
a month ago - InvestorPlace

Why Is CF Bankshares (CFBK) Stock Down 19% Today?

CF Bankshares stock is falling on Friday after the company launched a public offering for CFBK shares during early morning trading.

News Image
a month ago - InvestorPlace

Why Is Sprout Social (SPT) Stock Down 32% Today?

Sprout Social stock is down on Friday as SPT investors react to a revenue miss in Q1 and its weak guidance for the full year of 2024!

News Image
a month ago - InvestorPlace

Why Is Vaxxinity (VAXX) Stock Up 39% Today?

Vaxxinity stock is rising higher on Friday with heavy trading of VAXX shares as it remains volatile ahead of its delisting next week.

News Image
a month ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Pre-market stock movers are worth checking out this morning as we dive into all of the biggest news moving shares on Friday!

News Image
a month ago - InvestorPlace

Nike Layoffs 2024: What to Know About the Latest Nike Job Cuts

Nike layoffs are on the way as the athletic wear company is preparing to cut 740 jobs in two rounds at its global headquarters.

News Image
a month ago - InvestorPlace

Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?

Hepion Pharmaceuticals stock is falling on Monday as investors in HEPA learn of the company winding down a Phase 2b clinical trial.

News Image
a month ago - InvestorPlace

Why Is Vaxxinity (VAXX) Stock Down 58% Today?

Vaxxinity stock is falling hard on Monday after the company announced plans to voluntarily delist shares of VAXX stock next month.

News Image
a month ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start ofd the trading week with a look at the biggest pre-market stock movers traders need to watch on Monday morning!

News Image
a month ago - Vaxxinity, Inc.

Vaxxinity Issues Shareholder Letter

News Image
a month ago - Vaxxinity, Inc.

Vaxxinity Issues Shareholder Letter

CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company...

News Image
a month ago - Vaxxinity, Inc.

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company...

News Image
2 months ago - Vaxxinity, Inc.

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

Presentation will address the Company’s clinical data in Parkinson’s disease

News Image
2 months ago - Vaxxinity, Inc.

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

Presentation will address the Company’s clinical data in Parkinson’s disease

News Image
2 months ago - InvestorPlace

VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023

VAXX stock results show that Vaxxinity beat analyst estimates for earnings per share the fourth quarter of 2023.

News Image
2 months ago - BusinessInsider

VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxxinity (NASDAQ:VAXX) just reported results for the fourth quarter of 2023.Va...

News Image
2 months ago - Vaxxinity, Inc.

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...

News Image
3 months ago - Vaxxinity, Inc.

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024

UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patients

News Image
3 months ago - Vaxxinity, Inc.

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024

UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patients...